Gilead Japan Chief Disappointed by WHO’s Recommendation Against Veklury; Label Expansion Eyed for Moderately Ill Patients

Luc Hermans, Japan president of Gilead Sciences, on December 17 voiced his disappointment over the WHO’s recommendation against the use of the company’s antiviral Veklury (remdesivir) in patients hospitalized with COVID-19, stressing confidence in its evidence. Speaking at a webinar...read more